Treatment (T) | Challenge (C) | FI, g | FCR | bwc FCR | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1–7 d | 7–14 d | 14–21 d | 21–30 d | 1–30 d | 1–7 d | 7–14 d | 14–21 d | 21–30 d | 1–30 d |  | ||
CON | NE- | 160 | 344 | 665 | 1,536 | 2,705 | 1.11 | 1.32 | 1.59 | 1.87 | 1.63 | 1.62 |
STB | NE- | 163 | 357 | 653 | 1,555 | 2,727 | 1.12 | 1.36 | 1.47 | 1.78 | 1.57 | 1.54 |
CB | NE- | 161 | 346 | 663 | 1,564 | 2,734 | 1.08 | 1.31 | 1.50 | 1.77 | 1.56 | 1.52 |
CON | NE +  | 159 | 351 | 600 | 1,470 | 2,579 | 1.11 | 1.35 | 1.74 | 1.86 | 1.68 | 1.72 |
STB | NE +  | 159 | 349 | 598 | 1,492 | 2,598 | 1.08 | 1.33 | 1.71 | 1.84 | 1.63 | 1.66 |
CB | NE +  | 165 | 355 | 598 | 1,496 | 2,615 | 1.11 | 1.35 | 1.65 | 1.77 | 1.61 | 1.62 |
SEM2 | Â | 1.9 | 8.0 | 7.9 | 49.9 | 51.9 | 0.017 | 0.036 | 0.037 | 0.065 | 0.002 | 0.028 |
Treatment | ||||||||||||
 CON |  | 159 | 347 | 632 | 1,503 | 2,642 | 1.11 | 1.33 | 1.66 | 1.86 | 1.65a | 1.67a |
 STB |  | 161 | 353 | 625 | 1,523 | 2,663 | 1.10 | 1.34 | 1.59 | 1.81 | 1.60ab | 1.60b |
 CB |  | 163 | 351 | 631 | 1,530 | 2,675 | 1.10 | 1.33 | 1.57 | 1.77 | 1.58b | 1.57b |
 | Challenge |  |  |  |  |  |  |  |  |  |  |  |
 |   NE- | 161 | 349 | 660a | 1,551 | 2,722a | 1.10 | 1.33 | 1.52b | 1.81 | 1.59b | 1.56b |
 |   NE+  | 161 | 352 | 599b | 1,486 | 2,597b | 1.10 | 1.34 | 1.70a | 1.82 | 1.64a | 1.67a |
P-value | ||||||||||||
 T |  | 0.19 | 0.80 | 0.65 | 0.85 | 0.82 | 0.85 | 0.96 | 0.08 | 0.41 | 0.05 | 0.006 |
 C |  | 0.80 | 0.66 |  < 0.001 | 0.13 | 0.01 | 0.77 | 0.72 |  < 0.001 | 0.75 | 0.01 |  < 0.001 |
 T × C |  | 0.12 | 0.51 | 0.77 | 0.99 | 0.99 | 0.13 | 0.61 | 0.46 | 0.82 | 0.86 | 0.91 |